Lamivudine | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Lamivudine
U.S. EXCLUSIVITIES

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Lamivudine

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

52 API Suppliers, 33 USDMF, 16 CEP/COS, 1 JDMF, 14 EU WC, 4 KDMF, 15 NDC API, 20 Listed Suppliers, $ API Reference Price

52 API Suppliers
33 USDMF
16 CEP/COS
1 JDMF
14 EU WC
4 KDMF
15 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

15 Drugs in Development

15 Drugs in Development

INTERMEDIATES

3 Intermediates Suppliers

3 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

354 FDF Dossiers, 126 FDA Orange Book, 57 Europe, 23 Canada, 7 Australia, 111 South Africa, 30 Listed Dossiers

354 FDF Dossiers
126 FDA Orange Book
57 Europe
23 Canada
7 Australia
111 South Africa
30 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG, TABLET;ORAL - 150MG;200MG;300MG, TABLET;ORAL - 150MG, TABLET;ORAL - 300MG, TABLET;ORAL - 100MG;300MG;300MG, TABLET;ORAL - 300MG;300MG, TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 600MG BASE;EQ 50MG BASE;300MG
TABLET;ORAL - 150MG;200MG;300MG
TABLET;ORAL - 150MG
TABLET;ORAL - 300MG
TABLET;ORAL - 100MG;300MG;300MG
TABLET;ORAL - 300MG;300MG
TABLET;ORAL - EQ 600MG BASE;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 16 SPI Pharma, 2 Seqens, 4 DKSH, 5 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 25 BASF, 8 Beneo, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 2 Finar, 12 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 39 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 19 Roquette, 13 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

92 Fillers, Diluents & Binders, 53 Coating Systems & Additives, 45 Direct Compression, 33 Controlled & Modified Release, 32 Disintegrants & Superdisintegrants, 28 Thickeners and Stabilizers, 26 Solubilizers, 25 Granulation, 24 Taste Masking, 22 Co-Processed Excipients, 18 Chewable & Orodispersible Aids, 18 Parenteral, 15 Lubricants & Glidants, 15 Topical, 13 Film Formers & Plasticizers, 8 API Stability Enhancers, 8 Emulsifying Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Rheology Modifiers, 3 Surfactant & Foaming Agents

92 Fillers, Diluents & Binders
53 Coating Systems & Additives
45 Direct Compression
33 Controlled & Modified Release
32 Disintegrants & Superdisintegrants
28 Thickeners and Stabilizers
26 Solubilizers
25 Granulation
24 Taste Masking
22 Co-Processed Excipients
18 Chewable & Orodispersible Aids
18 Parenteral
15 Lubricants & Glidants
15 Topical
13 Film Formers & Plasticizers
8 API Stability Enhancers
8 Emulsifying Agents
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
4 Rheology Modifiers
3 Surfactant & Foaming Agents

DIGITAL CONTENT

4 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 102 NEWS #PharmaBuzz

4 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
102 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 49 Finished Drug Prices, 18 Annual Reports

3 US Medicaid Prescriptions
49 Finished Drug Prices
18 Annual Reports

MARKET PLACE

12 APIs, 10 FDF Dossiers

12 APIs
10 FDF Dossiers

PATENTS & EXCLUSIVITIES

21 US Patents, 6 US Exclusivities, 20 Health Canada Patents

21 US Patents
6 US Exclusivities
20 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 4 USP, 9 Others

3 EDQM
4 USP
9 Others

ANALYTICAL

1 BioAnalytical Methods, 1 Analytical Methods

1 BioAnalytical Methods
1 Analytical Methods

$ API Ref.Price (USD/KG) : 106 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

6 All

01 1MSD MERCK CO

02 5VIIV HLTHCARE

filter Product Reset all filters

6 All

01 4ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

02 1DOLUTEGRAVIR SODIUM; LAMIVUDINE

03 1DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

filter Exclusivity Expiration Date Reset all filters

6 All

01 12025-01-27

02 22026-06-15

03 22026-12-15

04 12027-04-05

filter Exclusivity Code Reset all filters

6 All

01 1M-294

02 3NPP

03 2PED

Product Main Page

MSD MERCK CO

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NPP

Exclusivity Expiration Date

2025-01-27

Application Number

210807

Product Number

1

Exclusivity Details

01

MSD MERCK CO

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

MSD MERCK CO

Singapore

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Exclusivity Code : NPP

Exclusivity Expiration Date : 2025-01-27

Application Number : 210807

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

VIIV HLTHCARE

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2026-12-15

Application Number

205551

Product Number

1

Exclusivity Details

02

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Antibody Engineering

Not Confirmed

VIIV HLTHCARE

United Kingdom

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Exclusivity Code : PED

Exclusivity Expiration Date : 2026-12-15

Application Number : 205551

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

VIIV HLTHCARE

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PED

Exclusivity Expiration Date

2026-12-15

Application Number

215413

Product Number

1

Exclusivity Details

03

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Antibody Engineering

Not Confirmed

VIIV HLTHCARE

United Kingdom

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Exclusivity Code : PED

Exclusivity Expiration Date : 2026-12-15

Application Number : 215413

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

VIIV HLTHCARE

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NPP

Exclusivity Expiration Date

2027-04-05

Application Number

211994

Product Number

1

Exclusivity Details

04

VIIV HLTHCARE

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Antibody Engineering

Not Confirmed

VIIV HLTHCARE

United Kingdom

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Exclusivity Code : NPP

Exclusivity Expiration Date : 2027-04-05

Application Number : 211994

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

VIIV HLTHCARE

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

NPP

Exclusivity Expiration Date

2026-06-15

Application Number

215413

Product Number

1

Exclusivity Details

05

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Antibody Engineering

Not Confirmed

VIIV HLTHCARE

United Kingdom

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Exclusivity Code : NPP

Exclusivity Expiration Date : 2026-06-15

Application Number : 215413

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

VIIV HLTHCARE

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

M-294

Exclusivity Expiration Date

2026-06-15

Application Number

205551

Product Number

1

Exclusivity Details

06

VIIV HLTHCARE

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Antibody Engineering

Not Confirmed

VIIV HLTHCARE

United Kingdom

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Exclusivity Code : M-294

Exclusivity Expiration Date : 2026-06-15

Application Number : 205551

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?